The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | Factors to consider when selecting between continuous and fixed-duration therapy in CLL
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares some insights into factors to consider when selecting between fixed-duration and continuous therapy in patients with chronic lymphocytic leukemia (CLL). Dr Munir explains that treatment is guided by several factors, including genetics and comorbidities, and further highlights that patient choice is important when making this decision. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
